NEW YORK CITY (dpa-AFX) - Wednesday, Blackstone Inc. (BX) announced a new partnership with Moderna, Inc. (MRNA) through a development and commercialization funding agreement, funds managed by Blackstone Life Sciences will provide up to $750 million to support Moderna's influenza program.
If successful, Blackstone Life Sciences may receive milestones and royalties from the resulting flu products.
Moderna will consider the funding as a deduction in research and development costs and will maintain complete ownership and oversight of the Company's influenza initiative.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX